Lexicon Pharmaceuticals (LXRX) Profit After Tax (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Profit After Tax data on file, last reported at -$1.2 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 95.24% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$26.3 million, a 85.09% increase from a year earlier, with the FY2025 full-year figure at -$50.4 million, up 74.82% from the prior year.
• Profit After Tax for Q1 2026 stood at -$1.2 million, up from -$15.6 million in the prior quarter.
• Over the last five years, Profit After Tax for LXRX reached as high as $3.3 million in Q2 2025 and fell as low as -$64.3 million in Q3 2024.
• Historically, Profit After Tax has averaged -$31.2 million across 5 years, with a median of -$30.0 million in 2022.
• Across the five-year window, Profit After Tax tumbled 112.99% in 2023 and surged 106.09% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$30.0 million in 2022, then sank by 64.25% to -$49.3 million in 2023, then soared by 31.68% to -$33.7 million in 2024, then jumped by 53.62% to -$15.6 million in 2025, then jumped by 92.3% to -$1.2 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$1.2 million in Q1 2026, -$15.6 million in Q4 2025, and -$12.8 million in Q3 2025.